Dr. Susan Shiff Ph.D. serves as Director of the Company. She has over 20 years of experience in the pharmaceutical industry as a leader in the development and implementation of evidence, access, and pricing strategies for products globally. Dr. Shiff joined Merck in June 2014 as Senior Vice President and head of the Center for Observational and Real-World Evidence. Before joining Merck, from October 2013 through May 2014, she served as Vice President of Global Health Economics, Data Sciences and Evidence-Based Medicine at Teva Pharmaceuticals. Previously, from June 2006 through September 2013, Dr. Shiff served at Pfizer, including as Vice President of Evidence-Based Medicine and Market Access in Global Primary Care as well as Vice President of Health Economics and Outcomes Research and Epidemiology in Emerging Markets. She has also held senior positions at Roche and Johnson & Johnson. Dr. Shiff began her career and spent four years at the Centers for Disease Control and Prevention. Dr. Shiff currently serves on the Boards of Synthace Limited and the Merck Global Health Innovation Fund. Dr. Shiff holds an M.B.A. from Cornell University and a Ph.D. from the University of California at Los Angeles.
Susan Shiff is 59, he's been the Director of Cara Therapeutics Inc since 2020. There are 3 older and 15 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Susan's mailing address filed with the SEC is C/O CARA THERAPEUTICS, INC., 400 ATLANTIC STREET, SUITE 500, STAMFORD, CT, 06901.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, eVentures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: